Biofilms and exopolysaccharides in Pseudomonas aeruginosa: pathogenesis, immune evasion, and lung-brain signaling during pneumonia [0.03%]
铜绿假单胞菌中的生物膜和外多糖：肺炎期间的致病性、免疫逃避及肺-脑信号传导
Shuaibing Zhang,Pierre Stallforth
Shuaibing Zhang
Robust neutralizing antibody response to the XBB.1.5 trivalent recombinant protein vaccine booster [0.03%]
针对XBB.1.5重组蛋白疫苗加强针的稳健中和抗体反应
Bing-Dong Zhan,Xue-Dong Song,Xin Yu et al.
Bing-Dong Zhan et al.
Novel pathomechanistic insights into lysosomal storage disorders: how neuron-intrinsic cGAS-STING signaling drives disease progression [0.03%]
溶酶体贮积病的新病理机制见解：神经元固有cGAS-STING信号通路如何促进疾病进展
Maximilian Frosch,Marco Prinz
Maximilian Frosch
Branched-chain amino acid transaminase 1 confers EGFR-TKI resistance through epigenetic glycolytic activation [0.03%]
支链氨基酸转氨酶1通过表观遗传学糖酵解激活介导EGFR-TKI耐药性
Tao Zhang,Zilu Pan,Jing Gao et al.
Tao Zhang et al.
Third-generation EGFR tyrosine kinase inhibitors (TKIs), exemplified by osimertinib, have demonstrated promising clinical efficacy in the treatment of non-small cell lung cancer (NSCLC). Our previous work has identified ASK120067 as a novel...
Ciprian Tomuleasa,Adrian-Bogdan Tigu,Raluca Munteanu et al.
Ciprian Tomuleasa et al.
Receptor tyrosine kinases (RTKs), a category of transmembrane receptors, have gained significant clinical attention in oncology due to their central role in cancer pathogenesis. Genetic alterations, including mutations, amplifications, and ...
Drug tolerant persister cell plasticity in cancer: A revolutionary strategy for more effective anticancer therapies [0.03%]
药物耐受性持久细胞的可塑性与癌症治疗：更有效的抗癌策略革命性方法
Jun He,Zejing Qiu,Jingjing Fan et al.
Jun He et al.
Non-genetic mechanisms have recently emerged as important drivers of anticancer drug resistance. Among these, the drug tolerant persister (DTP) cell phenotype is attracting more and more attention and giving a predominant non-genetic role i...
Gefitinib (an EGFR tyrosine kinase inhibitor) plus anlotinib (an multikinase inhibitor) for untreated, EGFR-mutated, advanced non-small cell lung cancer (FL-ALTER): a multicenter phase III trial [0.03%]
一项评价吉非替尼（表皮生长因子受体酪氨酸激酶抑制剂）联合阿帕替尼（一种多靶点激酶抑制剂）一线治疗携带EGFR突变的晚期非小细胞肺癌患者的有效性和安全性的Ⅲ期临床研究（FL-ALTER）
Hua-Qiang Zhou,Ya-Xiong Zhang,Gang Chen et al.
Hua-Qiang Zhou et al.
Dual inhibition of vascular endothelial growth factor and epidermal growth factor receptor (EGFR) signaling pathways offers the prospect of improving the effectiveness of EFGR-targeted therapy. In this phase 3 study (ClinicalTrial.gov: NCT0...
Current advance of nanotechnology in diagnosis and treatment for malignant tumors [0.03%]
纳米技术在恶性肿瘤诊断和治疗中的最新进展
Bilan Wang,Shiqi Hu,Yan Teng et al.
Bilan Wang et al.
Cancer remains a significant risk to human health. Nanomedicine is a new multidisciplinary field that is garnering a lot of interest and investigation. Nanomedicine shows great potential for cancer diagnosis and treatment. Specifically engi...
Potassium voltage-gated channel subfamily H member 2 (KCNH2) is a promising target for incretin secretagogue therapies [0.03%]
钾电压门控通道亚家族H成员2（KCNH2）是肠降糖素分泌促进疗法的一个颇有前景的作用靶点
Ying-Chao Yuan,Hao Wang,Ze-Ju Jiang et al.
Ying-Chao Yuan et al.
Derived from enteroendocrine cells (EECs), glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) are pivotal incretin hormones crucial for blood glucose regulation. Medications of GLP-1 analogs and GLP-1 recepto...
Mark Helm,Marie-Luise Winz
Mark Helm